A Nature-Derived Microbial Lotion for Eczema: Why a 28-Day Signal Needs a Placebo

Dr. Arsy Editorial Team · November 9, 2026

“Nature-derived” and “clinically effective” are different claims. In a 2026 pilot, people with atopic dermatitis used a lotion containing inactivated microbial extract on one side of the body and a placebo lotion on the other for 28 days. The report did not find a significant advantage for eczema severity or several barrier and microbiome measures. ^[10]

What was in the research question?

The investigators were exploring a hypothesis about environmental microbial exposure and skin health. The tested product contained a 1% inactivated microbial extract. Inactivated material is not the same thing as applying a living bacterial strain, and a supervised study lotion is not the same as applying soil or homemade mixtures to eczema. ^[10]

The comparison was randomized, placebo-controlled and double-blinded. Participants applied active and placebo preparations to opposite body sides, and no other creams were used on the examined areas at the same time. The reported measures included eczema severity, transepidermal water loss, skin color assessment, microbial composition and selected inflammatory markers. These design choices answer questions about the tested protocol, not all possible home routines. ^[10]

The result that a headline can miss

The report described the preparation as well tolerated under study supervision. Compared with placebo, it did not significantly improve atopic eczema severity, water loss, erythema, overall bacterial-community composition or inflammatory cytokine outcomes. Some markers fell on treated lesions, but the researchers could not separate those changes from what happened with placebo. A change after treatment is not automatically caused by the active ingredient. ^[10]

Because this was a short pilot, it does not rule out a benefit for another extract, dose or longer treatment, and it cannot establish long-term safety. Equally, it does not justify claiming that this lotion restores a microbiome or treats eczema in the general population. ^[10]

How does it differ from other approaches?

Studies of XZ.700 and SA.100 investigated bacterial-targeting proteins, whereas ShA9 and B244 involved selected living organisms. A different controlled trial tested a bacterial lysate. The measured outcomes and patients differed, so the results cannot be pooled informally under a single “natural probiotic” label. ^{[1][2][3][4][8]}

Early Roseomonas work and the later FB-401 comparison demonstrate why an encouraging first observation needs further testing. Other studies look at skin cultures, topical combinations, barrier measurements or changes during systemic treatment—none of which automatically proves that one consumer formula treats eczema. ^{[5][6][7][9][11][14][15][16][17][18]}

What to do if your skin is flaring

Choose skin care based on the actual label, personal tolerance and your clinician's plan. Do not apply garden soil, homemade cultures or food mixtures to inflamed skin. Bacterial colonization is not automatically infection; a clinician can evaluate warning signs such as increasing pain, warmth, pus, fever or rapidly worsening skin. ^[12][13]

Read the wider evidence in context

Skin-microbiome research includes studies of live organisms, inactive bacterial material, proteins targeting bacteria, and ordinary skin-care products. Clinical scores, itch reports, skin barrier tests and bacterial measures do not answer the same question. Guidelines support individualized eczema care and moisturization; studies of other formulas cannot be transferred to a different product. ^{[11][12][13][14][15][16][17][18][19][20]}

Dr. Arsy #003 in a daily routine

Explore Dr. Arsy™ Hydration Recovery Moisturizer #003, 4 oz, a fragrance-free moisturizer for dry, sensitive and eczema-prone skin. The studies discussed here did not test #003 and do not show that it alters the microbiome, treats eczema or treats infection. For babies, ask the child's clinician before choosing skin-care products.

Related reading

• Endolysin XZ.700 for Eczema: What a 39-Person Study Actually Found
• B244 for Eczema Itch: What the 547-Adult Trial Measured
• Staphylococcus hominis A9 and Eczema: Why a Safety Trial Was Not Proof of Clearance
• Can a Moisturizer Change the Eczema Microbiome? A 7-Day Study With 22 Analyzed
• Microbiome treatments: why later trials matter
• Eczema or skin infection? Warning signs and care

Research and clinical references

1. XZ.700: first-in-human randomized endolysin study.
2. SA.100: vehicle-controlled endolysin trial.
3. B244: phase 2b ammonia-oxidizing bacteria trial.
4. Staphylococcus hominis A9 phase 1 clinical trial.
5. FB-401: placebo-controlled Roseomonas trial.
6. First-in-human Roseomonas mucosa research.
7. Roseomonas mucosa research in children.
8. Lactobacillus lactis lysate: placebo-controlled pilot.
9. Moisturizer and farnesol: skin-microbiome experiment.
10. Inactivated environmental microbial extract: pilot trial.
11. Staphylococcus aureus and eczema severity: systematic review.
12. International Eczema Council: skin bacteria and infection.
13. Infectious complications of atopic dermatitis.
14. Topical niclosamide and the eczema skin microbiome.
15. Isosorbide diesters and the pediatric skin microbiome.
16. Antimicrobial-corticosteroid combinations and skin microbiome.
17. Systemic eczema therapies and skin bacteria: pilot research.
18. Emollients and skin-barrier function: systematic review.
19. AAD guideline: pediatric eczema management.
20. AAD guideline: adult eczema topical management.

Educational information; not a diagnosis or individual medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.